PT - JOURNAL ARTICLE AU - Sokratis A. Apostolidis AU - Mihir Kakara AU - Mark M. Painter AU - Rishi R. Goel AU - Divij Mathew AU - Kerry Lenzi AU - Ayman Rezk AU - Kristina R. Patterson AU - Diego A. Espinoza AU - Jessy C. Kadri AU - Daniel M. Markowitz AU - Clyde Markowitz AU - Ina Mexhitaj AU - Dina Jacobs AU - Allison Babb AU - Michael R. Betts AU - Eline T. Luning Prak AU - Daniela Weiskopf AU - Alba Grifoni AU - Kendall A. Lundgreen AU - Sigrid Gouma AU - Alessandro Sette AU - Paul Bates AU - Scott E. Hensley AU - Allison R. Greenplate AU - E. John Wherry AU - Rui Li AU - Amit Bar-Or TI - Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy AID - 10.1101/2021.06.23.21259389 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.23.21259389 4099 - http://medrxiv.org/content/early/2021/06/30/2021.06.23.21259389.short 4100 - http://medrxiv.org/content/early/2021/06/30/2021.06.23.21259389.full AB - SARS-CoV-2 mRNA vaccination in healthy individuals generates effective immune protection against COVID-19. Little is known, however, about the SARS-CoV-2 mRNA vaccine-induced responses in immunosuppressed patients. We investigated induction of antigen-specific antibody, B cell and T cell responses in patients with multiple sclerosis on anti-CD20 (MS-aCD20) monotherapy following SARS-CoV-2 mRNA vaccination. Treatment with aCD20 significantly reduced Spike and RBD specific antibody and memory B cell responses in most patients, an effect that was ameliorated with longer duration from last aCD20 treatment and extent of B cell reconstitution. In contrast, all MS-aCD20 patients generated antigen-specific CD4 and CD8 T-cell responses following vaccination. However, treatment with aCD20 skewed these responses compromising circulating Tfh responses and augmenting CD8 T cell induction, while largely preserving Th1 priming. These data also revealed underlying features of coordinated immune responses following mRNA vaccination. Specifically, the MS-aCD20 patients who failed to generate anti-RBD IgG had the most severe defect in cTfh cell responses and more robust CD8 T cell responses compared to those who generated anti-RBD IgG, whose T cell responses were more similar to healthy controls. These data define the nature of SARS-CoV-2 vaccine-induced immune landscape in aCD20-treated patients, and provide insights into coordinated mRNA vaccine-induced immune responses in humans. Our findings have implications for clinical decision-making, patient education and public health policy for patients treated with aCD20 and other immunosuppressed patients.Competing Interest StatementSEH has received consultancy fees from Sanofi Pasteur, Lumen, Novavax, and Merk for work unrelated to this report. EJW is consulting or is an advisor for Merck, Marengo, Janssen, Related Sciences, Synthekine and Surface Oncology. EJW is a founder of Danger Bio, Surface Oncology and Arsenal Biosciences. EJW is an inventor on a patent (US Patent number 10,370,446) submitted by Emory University that covers the use of PD-1 blockade to treat infections and cancer. AS is a consultant for Gritstone, Flow Pharma, CellCarta, Arcturus, Oxfordimmunotech, and Avalia. La Jolla Institute for Immunology has filed for patent protection for various aspects of T cell epitope and vaccine design work. ETLP is consulting or is an advisor for Roche Diagnostics, Enpicom, The Antibody Society, IEDB, and The American Autoimmune Related Diseases Association. DJ is on the advisory boards for Biogen, Genentech, Novartis, EMD Serono, Banner Life Sciences, Bristol Myers Squibb and Sanofi Genzyme and has received research support (clinical trial site PI) from Biogen, Genentech and UCLA. ABO has participated as a speaker in meetings sponsored by and received consulting fees and/or grant support from Accure, Atara Biotherapeutics, Biogen, BMS/Celgene/Receptos, GlaxoSmithKline, Gossamer, Janssen/Actelion, Medimmune, Merck/EMD Serono, Novartis, Roche/Genentech, Sanofi-Genzyme.Funding StatementThis work was supported by grants from the NIH AI105343, AI082630, AI108545, AI155577, AI149680 (to EJW), AI152236 (to PB), P30-AI0450080 (to ETLP), R01 AI118694 and UC4 DK112217 (to M.R.B.), T32 AR076951-01 (to SAA), T32 CA009140 (to DM), U19AI082630 (to SEH and EJW), UM1 AI144288 (ABO), NMSS SI-2011-37160 (ABO), funding from the Allen Institute for Immunology (to SAA, EJW), Chen Family Research Fund (to SAA), the National Multiple Sclerosis Society-American Brain Foundation Clinician Scientist Award (to MK), the Parker Institute for Cancer Immunotherapy (to EJW), the Penn Center for Research on Coronavirus and Other Emerging Pathogens (to PB), the University of Pennsylvania Perelman School of Medicine COVID Fund (to RRG, EJW), the University of Pennsylvania Institute for Immunology Glick COVID-19 research award (to M.R.B.), the University of Pennsylvania Perelman School of Medicine 21st Century Scholar Fund (to RRG), and a philanthropic gift from Jeffrey Lurie, Joel Embiid, Josh Harris, and David Blitzer (to SEH). Work in the Wherry lab is supported by the Parker Institute for Cancer Immunotherapy. This work was also supported by NIH contract Nr. 75N9301900065 (to DW, AS).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Pennsylvania IRB IRB Protocol #: 848377 Protocol title: The Multiple Sclerosis COVID-19 Vaccine-Response StudyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the main text or the supplementary materials. Raw data files and reagents are available from the authors upon request.